AYOXXA Biosystems GmbH

  • Land: Deutschland

Nachricht vom 18.04.2018 | 09:00

AYOXXA launches LUNARIS(TM) Human 12-Plex Th17 Kit expanding its portfolio for fully scalable biomarker analysis

DGAP-News: AYOXXA Biosystems GmbH / Key word(s): Product Launch

18.04.2018 / 09:00
The issuer is solely responsible for the content of this announcement.

AYOXXA launches LUNARISTM Human 12-Plex Th17 Kit expanding its portfolio for fully scalable biomarker analysis

  • LUNARISTM Th17 Cell Biology Kits for the quantitative analysis of highly specific soluble pro-inflammatory Th17 cell markers in translational research
  • In combination with the LUNARISTM Mouse 12-Plex Th17 Kit, the new product allows researchers to conduct comparative studies of Th17 cell activation and its effects on immune-mediated diseases from model to man without changing platforms
  • Launch marks a further step in establishing AYOXXA's LUNARISTM as the technology of choice to enable translational research from lab to clinic - from model to man - from data to insight

Cologne, Germany, April 18, 2018 - AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARISTM Human 12-Plex Th17 Kit for the quantitative validation of soluble pro-inflammatory T helper 17 (Th17) cell-related markers. The newly introduced panel complements the already commercially available LUNARISTM Mouse 12-Plex Th17 Kit. In combination, these kits allow researchers to conduct comparative studies of Th17 cell activation and its effects on immune-mediated diseases from mouse model into clinical research using a single validated platform.

"With the launch of the new LUNARISTM Th17 Kit we have strategically expanded our portfolio of kits to further establish our platform as the technology of choice for translational research. It allows scientists to analyze disease-related biomarkers and to follow their results from laboratory models to human clinical studies, from model to man, from data to insight," said Rodney Turner, CEO of AYOXXA. "Our growing portfolio of disease-related panels such as the new LUNARISTM Th17 Kits fuels the understanding of underlying complex biological mechanisms and as a result the development of related biomarker signatures and novel targets for drug development, patient stratification and monitoring."

"As the commercial partner for translational content discovery, AYOXXA is continuously expanding its portfolio of dedicated biomarker panels with a strong focus on biological relevance and clinical deployment," said Wolfgang Kintzel, Co-CEO of AYOXXA. "The superiority of our LUNARISTM system in terms of data quality, minimal sample volume requirements and scalability in combination with highest flexibility in sample sources and analytical formats, positions us as the leading company in translational protein research. We are experiencing increasing interest in our technology today and are further executing on multiple pharma and clinical panel development collaborations.

LUNARISTM Human & Mouse Th17 Cell Biology Kits
Validated, scalable, robust

Comparable to the mouse version, the LUNARISTM Human 12-Plex Th17 Kits comprises a panel of highly-specific antibody pairs against CCL20, IFN-γ, IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17E, IL-17F, IL-21, IL-23 and TGF-β1. These cytokines are involved in regulating the differentiation and effector functions of Th17 cells in different pathogenic conditions including autoimmune disorders, immune-mediated diseases as well as allergy, cancer, microbial defense and transplantation.

Particularly noteworthy is the opportunity to measure the active form of transforming growth factor beta 1 (TGF-β1) which is not included in most comparable assays. The absence or presence of TGF-β1, in combination with other cytokines such as IL-1β, IL-6 or IL-23, which are also covered by this assay, regulates the differentiation of Th17 cells and is thereby important for the final outcome and character (anti-infective or pathogenic) of immune responses.

LUNARISTM Th17 Cell Biology Kits are optimized to run on AYOXXA's proprietary multiplex protein analysis system LUNARISTM, an automated system that can be readily integrated into any laboratory routine and is optimized to provide an easy-to-use, standardized workflow from sample to result. It combines the familiarity of standard immunoassay workflow with unmatched capability for low sample volume, scalability for low- to high-throughput applications and market leading data quality. The system comprises a dedicated LUNARISTM reader and best-in-class LUNARISTM software for image-based analysis with a 100% read-out.

LUNARISTM kits follow a classical sandwich immunoassay principle with fluorescence readout. The BioChips and assays are painstakingly optimized using the best quality antibody-pairs to ensure the highest assay sensitivity and specificity with minimal cross-reactivity in a multiplex format. Due to the innovative BioChip format and planar geometry, LUNARISTM assays can be performed with sample volumes as low as 3µL - which represents only 1/10 of the volume required by comparable multiplex technologies. This low minimum volume requirement enables multiplex protein analysis from valuable and scarce sample sources.

The new LUNARISTM Human12-Plex Th17 Kit adds to the already existing portfolio of standardized biomarker kits for the study of inflammation and immune response, as well as assay kits optimized for an extensive range of cytokines and growth factors, and those optimized for specific application areas, such as ophthalmolog. For more information on the LUNARISTM Kit portfolio, please visit AYOXXA's website.

About Th17 cells:

The dysregulation of the balance of Th17 cells and other immune cells has been associated with a variety of pathogenic conditions including rheumatoid arthritis, psoriasis and multiple sclerosis. Th17 cells can be broadly divided into two groups, the host protective cells that express both IL-17A and IL-17F and IL-10 and the highly inflammatory population which expresses IL-17A, IL-17F, IL-22 and IFN-γ. Th17 cells activated by transforming growth factor-β1 (TGF-β1) and IL-6 promote mucosal defense, barrier tissue integrity and curtails immunopathogenic responses, whereas IL-1β and IL-23-activated Th17 cells have been shown to cause chronic tissue inflammation during infection, granuloma formation and autoimmune response.


AYOXXA Biosystems GmbH is an international life science company based in Cologne (Germany) with offices in Boston, MA (USA) and Singapore. AYOXXA enables its customers and partners to utilize its reliable and optimized platform technology to fuel breakthroughs in all areas of life science research and to enhance success in translational science.

With LUNARISTM, its proprietary innovative beads-on-a-chip multiplexing platform for advanced protein analysis, the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and across drug development. With its advantages in terms of quality, flexibility, robustness and efficiency, LUNARISTM enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker analysis assays, with a focus on the biology of inflammation and immune response.

For more information, please visit www.ayoxxa.com

Follow AYOXXA on LinkedIn.

LUNARISTM products are intended "for research use only" and may not be used in diagnostic procedures.

Media Contacts:

AYOXXA Biosystems GmbH MC Services AG
Dr. Marion Lammertz Dr. Solveigh Mähler
Marketing Manager Communications  
P: +49 (0) 221 222529 41 +49 (0) 211 529 252 19
E: marion.lammertz@ayoxxa.com solveigh.maehler@mc-services.eu

18.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Interview im Fokus

HanseYachts: „Der ideale Zeitpunkt für den Kauf“

Die Übernahme des Katamaran-Herstellers Privilège bringt die HanseYachts AG dem Umsatzziel von 200 Mio. Euro einen bedeutenden Schritt näher. „Der Katamaran-Markt ist das derzeit am stärksten wachsende Segment im Yacht-Geschäft. Privilège ist weltweit in Preis und Qualität die Nummer eins“, so CEO Dr. Jens Gerhardt. Zudem sei der Deal ein wichtiger Faktor, um die EBITDA-Marge auf 10 bis 12 % zu steigern. Im Financial.de-Interview spricht der Konzernlenker über die aktuellsten Trends im Yacht-Geschäft, die laufende Barkapitalerhöhung sowie die Weltpremieren in Cannes.


Fonds Research 2019: S.E.A. Asian High Yield Bond bietet attraktive Investitionschance

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter auch den S.E.A. Asian High Yield Bond (ISIN: LU1138637738), der eine gute Anlagechance anbietet mit einer Strategie, die kaum reproduzierbar ist. Insbesondere vor dem Hintergrund des anhaltenden Niedrigzinsniveaus sehen wir den Anleihefonds als äußerst attraktive Investitionschance, um nachhaltige und volatilitätsarme Renditen zu erzielen. Wir haben den S.E.A. Asian High Yield Bond mit 4 von 5 Falken eingestuft.

News im Fokus

Vonovia SE: Response to the Berlin Government's Plans for an Absolute Rent Ceiling in Berlin

26. August 2019, 06:30

Aktueller Webcast

SeaChange Corporation

Second Quarter 2020 Earnings Conference Call

29. August 2019

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy

23. August 2019